The estimated Net Worth of Jason M. Marks is at least $19.7 Tisíc dollars as of 19 August 2022. Mr Marks owns over 33,334 units of Amarin Corp stock worth over $19,667 and over the last 3 years he sold AMRN stock worth over $0.
Mr has made over 1 trades of the Amarin Corp stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 33,334 units of AMRN stock worth $19,667 on 19 August 2022.
The largest trade he's ever made was exercising 33,334 units of Amarin Corp stock on 19 August 2022 worth over $19,667. On average, Mr trades about 6,667 units every 0 days since 2021. As of 19 August 2022 he still owns at least 33,334 units of Amarin Corp stock.
You can see the complete history of Mr Marks stock trades at the bottom of the page.
Jason M. Marks J.D. is the Chief Legal Officer & Corp. Sec. at Amarin Corp.
Mr D is 44, he's been the Chief Legal Officer & Corp. Sec. of Amarin Corp since . There are 17 older and no younger executives at Amarin Corp. The oldest executive at Amarin Corp is Patrick O'Sullivan, 78, who is the Non-Executive Independent Director.
Jason's mailing address filed with the SEC is C/O BIOMX INC., 22 EINSTEIN ST., FLOOR 4, 440 US HIGHWAY 22, NESS ZIONA, L3, 7414003.
Over the last 13 years, insiders at Amarin Corp have traded over $25,876,836 worth of Amarin Corp stock and bought 581,426 units worth $751,974 . The most active insiders traders include John F Thero, Steven B Ketchum a David M Stack. On average, Amarin Corp executives and independent directors trade stock every 10 days with the average trade being worth of $29,442. The most recent stock trade was executed by Aaron Berg on 2 August 2024, trading 160,000 units of AMRN stock currently worth $102,400.
amarin corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. vascepa® (icosapent ethyl) is amarin's first fda approved product and is available in the united states by prescription. for more information about vascepa visit www.vascepa.com.
Amarin Corp executives and other stock owners filed with the SEC include: